Details of the Drug

General Information of Drug (ID: DM5QF9V)

Drug Name

Tamsulosin

Synonyms

Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Benign prostatic hyperplasia	GA90	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

408.5

Topological Polar Surface Area (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The clearance of drug is 2.88 L/h [5]
Elimination: 97% of an orally administered does is recovered in studies, which 76% in the urine and 21% in the feces after 168 hours. 8.7% of the dose is excreted as unmetabolized tamsulosin [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 14.9 +/- 3.9 hours [7]
Metabolism: The drug is metabolized via the liver [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03256 micromolar/kg/day [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [7]
Vd: The volume of distribution (Vd) of drug is 16 L [5]

Chemical Identifiers

Formula: C20H28N2O5S
IUPAC Name: 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
Canonical SMILES: CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
InChI: InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
InChIKey: DRHKJLXJIQTDTD-OAHLLOKOSA-N

Cross-matching ID

PubChem CID: 129211
ChEBI ID: CHEBI:9398
CAS Number: 106133-20-4
DrugBank ID: DB00706
TTD ID: D05MBZ
INTEDE ID: DR1530
ACDINA ID: D00651

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Modulator	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Benign prostatic hyperplasia

ICD Disease Classification

GA90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor alpha-1A (ADRA1A)	DTT	ADRA1A	9.43E-01	-0.03	-0.25
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tamsulosin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Terazosin.	Prostate hyperplasia [GA90]	[37]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Silodosin.	Prostate hyperplasia [GA90]	[37]
-----------

Coadministration of a Drug Treating the Disease Different from Tamsulosin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Tamsulosin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[38]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Tamsulosin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[39]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Tamsulosin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[40]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Tamsulosin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Tamsulosin caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Tamsulosin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Tamsulosin caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Cariprazine.	Bipolar disorder [6A60]	[41]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Tamsulosin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[42]
Tucatinib	DMBESUA	Major	Decreased metabolism of Tamsulosin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Tamsulosin caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[40]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Tamsulosin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[39]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Tamsulosin caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[39]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Tamsulosin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[40]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Tamsulosin caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[39]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Selegiline.	Depression [6A70-6A7Z]	[43]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Isocarboxazid.	Depression [6A70-6A7Z]	[43]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Tranylcypromine.	Depression [6A70-6A7Z]	[43]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Tamsulosin and OPC-34712.	Depression [6A70-6A7Z]	[41]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Phenelzine.	Depression [6A70-6A7Z]	[43]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Tamsulosin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Tamsulosin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Tamsulosin caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[45]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Tamsulosin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[40]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Tamsulosin caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[39]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Tamsulosin caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[39]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Tamsulosin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[40]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Tamsulosin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[40]
Telaprevir	DMMRV29	Major	Decreased metabolism of Tamsulosin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[40]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Procarbazine.	Hodgkin lymphoma [2B30]	[43]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Tamsulosin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Tamsulosin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Saquinavir	DMG814N	Major	Decreased metabolism of Tamsulosin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Tamsulosin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Tamsulosin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Tamsulosin caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[39]
Conivaptan	DM1V329	Major	Decreased metabolism of Tamsulosin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Tamsulosin caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[39]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tamsulosin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[46]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Propiomazine.	Insomnia [7A00-7A0Z]	[41]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Tamsulosin and ITI-007.	Insomnia [7A00-7A0Z]	[41]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Tamsulosin caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[38]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Tamsulosin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
Ceritinib	DMB920Z	Major	Decreased metabolism of Tamsulosin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[40]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tamsulosin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[47]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Tamsulosin caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Tamsulosin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Idelalisib	DM602WT	Major	Decreased metabolism of Tamsulosin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Tamsulosin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[39]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tamsulosin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[38]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Tamsulosin caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[39]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Ozanimod.	Multiple sclerosis [8A40]	[43]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Tamsulosin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[39]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Promethazine.	Nausea/vomiting [MD90]	[41]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Tamsulosin caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[39]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Tamsulosin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[39]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Tamsulosin caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[39]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Tamsulosin caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[39]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Tamsulosin caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[39]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Tamsulosin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[48]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Safinamide.	Parkinsonism [8A00]	[43]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Rasagiline.	Parkinsonism [8A00]	[43]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tamsulosin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[49]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Tamsulosin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[50]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Tamsulosin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[40]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Tamsulosin caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[39]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Tamsulosin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[51]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Tolazoline.	Pulmonary hypertension [BB01]	[37]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Mesoridazine.	Schizophrenia [6A20]	[41]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Aripiprazole.	Schizophrenia [6A20]	[41]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Iloperidone.	Schizophrenia [6A20]	[41]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Perphenazine.	Schizophrenia [6A20]	[41]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Molindone.	Schizophrenia [6A20]	[41]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Thiothixene.	Schizophrenia [6A20]	[41]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Trifluoperazine.	Schizophrenia [6A20]	[41]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Amisulpride.	Schizophrenia [6A20]	[41]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Tamsulosin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[39]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Tamsulosin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[38]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Tamsulosin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
LEE011	DMMX75K	Moderate	Decreased metabolism of Tamsulosin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[39]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Tamsulosin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[52]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[41]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Tamsulosin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[53]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Tamsulosin caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[39]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Tamsulosin caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[39]
-----------


⏷ Show the Full List of 85 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium stearate	E00244	15324	lubricant
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate	E00395	110800	Emollient; Opacifying agent; Surfactant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tamsulosin 0.4 mg capsule	0.4 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 488).
2	Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Dunn CJ, Matheson A, Faulds DM: Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-61.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Greenblatt DJ, Wright CE: Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet. 1993 Jun;24(6):453-71. doi: 10.2165/00003088-199324060-00003.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
30	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
31	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
32	Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
33	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
34	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
35	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
36	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
37	Product Information. Flomax (tamsulosin). Boehringer-Ingelheim, Ridgefield, CT.
38	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
39	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
40	Cerner Multum, Inc. "Australian Product Information.".
41	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
42	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
43	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
44	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
45	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
46	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
47	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
49	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
50	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
51	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
52	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
53	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.